Format

Send to

Choose Destination
Anesth Analg. 2010 Jan 1;110(1):21-9. doi: 10.1213/ANE.0b013e3181c0ea6d. Epub 2009 Nov 12.

The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.

Author information

1
Department of Anesthesia, University of Toronto, and Toronto General Hospital, Toronto, ON, Canada M5G 2C4. keyvan.karkouti@uhn.on.ca

Abstract

BACKGROUND:

Aprotinin is superior to other antifibrinolytic drugs for preventing major blood loss after cardiac surgery but may also increase perioperative mortality. It remains unclear whether its risk-benefit profile differs among low-, moderate-, and high-risk cardiac surgical patients.

METHODS:

In this retrospective single-center cohort study, we included 15,365 patients who underwent cardiac surgery with cardiopulmonary bypass from 2000 to 2008. Of these, 1017 received aprotinin (6 x 10(6) U) and 14,358 received tranexamic acid (50-100 mg/kg). Propensity score methods were used to create a matched-pairs cohort (n = 1544) that adjusted for important between-group differences. The influence of patients' risk status on aprotinin's association with in-hospital mortality, morbidity, and blood loss was measured.

RESULTS:

In the matched set, aprotinin was only associated with increased acute kidney injury (> 50% decrease in estimated glomerular filtration or dialysis; odds ratio 1.5; 95% confidence interval [CI] 1.1-2.1). Patients' risk status significantly influenced the associations of aprotinin with mortality, acute kidney injury, and massive blood loss (transfusion of > or = 10 U of red blood cells or need for surgical reexploration). Among high-risk patients, the respective odds ratios were 0.6 (CI 0.3-1.0), 1.1 (CI 0.7-1.7), and 0.7 (CI 0.4-1.04), and among low- to moderate-risk patients, they were 1.5 (CI 0.9-2.7), 2.2 (CI 1.4-3.5), and 1.2 (CI 0.9-1.07) (Breslow-Day test for homogeneity of odds ratios between high-risk versus low- to moderate-risk patients: P < 0.05 for all 3 outcomes).

CONCLUSIONS:

Aprotinin tends to have a better risk-benefit profile than tranexamic acid in high-risk, but not low- to moderate-risk, patients. Its use in high-risk cases may therefore be warranted.

PMID:
19910626
DOI:
10.1213/ANE.0b013e3181c0ea6d
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center